Search details
1.
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Future Oncol
; 19(5): 345-353, 2023 Feb.
Article
in English
| MEDLINE | ID: mdl-36815271
2.
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood
; 136(18): 2038-2050, 2020 10 29.
Article
in English
| MEDLINE | ID: mdl-32731259
3.
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
N Engl J Med
; 378(25): 2399-2410, 2018 Jun 21.
Article
in English
| MEDLINE | ID: mdl-29856685
4.
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose-expansion cohort.
Am J Hematol
; 96(4): 428-435, 2021 04 01.
Article
in English
| MEDLINE | ID: mdl-33421178
5.
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.
Hematol Oncol
; 38(3): 353-362, 2020 Aug.
Article
in English
| MEDLINE | ID: mdl-32053229
6.
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Am J Hematol
; 94(12): 1325-1334, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31490009
7.
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Lancet Oncol
; 18(2): 241-250, 2017 Feb.
Article
in English
| MEDLINE | ID: mdl-27956157
8.
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment.
Br J Clin Pharmacol
; 82(3): 696-705, 2016 09.
Article
in English
| MEDLINE | ID: mdl-27115790
9.
Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation.
Blood
; 120(3): 560-8, 2012 Jul 19.
Article
in English
| MEDLINE | ID: mdl-22510871
10.
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
Blood
; 119(24): 5661-70, 2012 Jun 14.
Article
in English
| MEDLINE | ID: mdl-22555973
11.
BTK Inhibitors in the Frontline Management of Waldenström Macroglobulinemia.
Hematol Oncol Clin North Am
; 37(4): 707-717, 2023 Aug.
Article
in English
| MEDLINE | ID: mdl-37246088
12.
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
Nat Med
; 29(2): 422-429, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36690811
13.
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients.
Semin Hematol
; 60(2): 73-79, 2023 03.
Article
in English
| MEDLINE | ID: mdl-37099027
14.
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
J Clin Oncol
; 40(1): 52-62, 2022 01 01.
Article
in English
| MEDLINE | ID: mdl-34606378
15.
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.
Clin Cancer Res
; 27(21): 5793-5800, 2021 11 01.
Article
in English
| MEDLINE | ID: mdl-34380643
16.
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.
J Clin Oncol
; 38(11): 1126-1137, 2020 04 10.
Article
in English
| MEDLINE | ID: mdl-31652094
17.
Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
Leuk Lymphoma
; 59(11): 2588-2594, 2018 11.
Article
in English
| MEDLINE | ID: mdl-29616843
18.
Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
Nat Med
; 29(12): 3271, 2023 Dec.
Article
in English
| MEDLINE | ID: mdl-36932247
19.
Oprozomib in patients with newly diagnosed multiple myeloma.
Blood Cancer J
; 9(9): 66, 2019 08 16.
Article
in English
| MEDLINE | ID: mdl-31420532
20.
Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
J Hematol Oncol
; 7: 24, 2014 Mar 19.
Article
in English
| MEDLINE | ID: mdl-24642247